NeoGenomics, Inc. (NEO): Price and Financial Metrics
NeoGenomics, Inc. (NEO)
Today's Latest Price: $34.23 USD
Updated Feb 18 2:03pm
Add NEO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
NEO Stock Summary
- With a price/earnings ratio of 1,639.5, Neogenomics Inc P/E ratio is greater than that of about 99.56% of stocks in our set with positive earnings.
- Price to trailing twelve month operating cash flow for NEO is currently 95.38, higher than 96.5% of US stocks with positive operating cash flow.
- As for revenue growth, note that NEO's revenue has grown 41.18% over the past 12 months; that beats the revenue growth of 87.33% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Neogenomics Inc, a group of peers worth examining would be LYV, GRUB, MGM, DAKT, and LAKE.
- NEO's SEC filings can be seen here. And to visit Neogenomics Inc's official web site, go to www.neogenomics.com.
NEO Stock Price Chart More Charts
NEO Price/Volume Stats
| Current price | $34.23 | 52-week high | $34.97 |
| Prev. close | $34.18 | 52-week low | $16.30 |
| Day low | $34.10 | Volume | 251,563 |
| Day high | $34.97 | Avg. volume | 793,716 |
| 50-day MA | $30.48 | Dividend yield | N/A |
| 200-day MA | $24.76 | Market Cap | 3.57B |
NeoGenomics, Inc. (NEO) Company Bio
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company was founded in 2001 and is based in Fort Myers, Florida.
NEO Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $34.23 | $9.32 | -73% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Neogenomics Inc. To summarize, we found that Neogenomics Inc ranked in the 24st percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for NEO, they are:
- The compound growth rate in the free cash flow of Neogenomics Inc over the past 5.51 years is 0.5%; that's higher than 80.52% of free cash flow generating stocks in the Healthcare sector.
- The business' balance sheet suggests that 4% of the company's capital is sourced from debt; this is greater than merely 13.48% of the free cash flow producing stocks we're observing.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -73% |
| 1% | -73% |
| 2% | -73% |
| 3% | -72% |
| 4% | -72% |
| 5% | -72% |
Want more companies with a valuation profile/forecast similar to that of Neogenomics Inc? See OFIX, XRAY, GKOS, WST, and DHR.
Top Stories View All
Have Shares of Shopify (SHOP) Run Too Far, Too Fast?
Best & Worst Performing Stock Industries for February 17, 2020
Best & Worst Performing Small Cap Stocks for February 17, 2020
Best & Worst Performing Mid Cap Stocks for February 17, 2020
Best & Worst Performing Large Cap Stocks for February 17, 2020
View All Top Stories
Loading social stream, please wait...